Clinical Daily Summary
Clinical Daily Summary: What Happened on November 19, 2026
Study characterizes potentially fatal enterocolitis after cilta-cel CAR T therapy
Biogen also reported two-year diranersen results from an ongoing Alzheimer’s study, including data from its open-label extension.
Today in brief
A multicenter study classified 41 patients treated with cilta-cel as having immune effector cell-associated enterocolitis. Seventeen had died while the condition was active at last follow-up.1 A separate MD Anderson cohort identified nine cases and found CAR T cells to be the principal cause in those patients. The reason for the gut’s vulnerability remains unclear.2
Biogen reported two-year diranersen results in early Alzheimer’s disease. In an ongoing open-label extension, the 60 mg twice-yearly group showed the largest reported effects across several measures.3
Enterocolitis after cilta-cel was active at death in 17 patients
Researchers reviewed 54 suspected gastrointestinal toxicity cases from eight institutions and classified 41 of 53 evaluable patients as having enterocolitis after cilta-cel treatment for multiple myeloma.1 Immunohistochemistry, a test that detects specific proteins in tissue, confirmed 31 cases. Researchers considered 10 probable.1
Among 1,308 recipients treated through September 2025, the estimated cumulative incidence was 3.0%. The authors cautioned that the referral-based estimate may not represent the wider population.1 Symptoms began a median of 75 days after infusion. Of 40 patients with diarrhea, 34 had severe symptoms.1
At last follow-up, 13 patients had recovered, 11 still had symptoms, and 17 had died while enterocolitis was active.1 Thirty patients required nutrition delivered directly into the bloodstream. Delayed neurological toxicity occurred in 17 patients.1
A separate MD Anderson cohort identified nine cases among 158 cilta-cel recipients, with estimated incidence of 5.1% at six months and 5.7% overall.2 The investigators identified CAR T cells as the principal cause in those cases. CAR T cell persistence in blood was 100 times greater than in patients without enterocolitis.2
The MD Anderson team found no evidence that vector integration caused mutations. The reason for the gut’s vulnerability remains unclear.2 The consortium authors called for systematic assessment and early targeted treatment of the potentially fatal condition.1
Biogen reports diranersen results from an ongoing Alzheimer’s extension
Biogen reported two-year data from CELIA, a Phase II study of intrathecal diranersen in 416 people with mild cognitive impairment or mild dementia due to Alzheimer’s disease.3 At week 96 of the ongoing open-label extension, participants assigned to 60 mg every six months showed the largest reported effects across cognition, daily function, and disease progression measures.3
In that group, worsening on the CDR-SB measure was 38% slower than in placebo-equivalent controls, a 1.09-point difference.3 Biogen also reported effects of 54% on ADAS-Cog13, 30% on ADCS-ADL-MCI, 38% on ADCOMS, 46% on iADRS, and 38% on MMSE.3
The trial’s primary outcome assessed dose response in CDR-SB change at week 76. The week-96 results came from an open-label extension, not the original placebo-controlled period.3 Biogen said clinical benefits appeared at every tested dose and that treatment was generally well tolerated over two years, with no new safety concerns.3
Also published
- STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment STAT Biotech
- Keeping Patients in the Loop as AI Enters Clinical Research: Q&A with Stacy Hurt Pharmaceutical Executive
- Mixed results for experimental Alzheimer's therapies at CTAD pharmaphorum
- The new reality of early‑phase diabetes trials pharmaphorum